DE69535883D1 - Muteine von ifn-beta - Google Patents
Muteine von ifn-betaInfo
- Publication number
- DE69535883D1 DE69535883D1 DE69535883T DE69535883T DE69535883D1 DE 69535883 D1 DE69535883 D1 DE 69535883D1 DE 69535883 T DE69535883 T DE 69535883T DE 69535883 T DE69535883 T DE 69535883T DE 69535883 D1 DE69535883 D1 DE 69535883D1
- Authority
- DE
- Germany
- Prior art keywords
- ifn
- beta
- those
- muteins
- recombinant dna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/565—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/213,448 US5545723A (en) | 1994-03-15 | 1994-03-15 | Muteins of IFN-β |
PCT/US1995/003206 WO1995025170A1 (en) | 1994-03-15 | 1995-03-13 | NOVEL MUTEINS OF IFN-$g(b) |
Publications (1)
Publication Number | Publication Date |
---|---|
DE69535883D1 true DE69535883D1 (de) | 2008-12-24 |
Family
ID=22795174
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69535883T Expired - Lifetime DE69535883D1 (de) | 1994-03-15 | 1995-03-13 | Muteine von ifn-beta |
Country Status (12)
Country | Link |
---|---|
US (2) | US5545723A (de) |
EP (1) | EP0750668B1 (de) |
JP (2) | JP3822903B2 (de) |
AT (1) | ATE414152T1 (de) |
AU (1) | AU695208B2 (de) |
CA (1) | CA2185352C (de) |
DE (1) | DE69535883D1 (de) |
DK (1) | DK0750668T3 (de) |
FI (1) | FI120356B (de) |
NO (1) | NO318989B1 (de) |
NZ (2) | NZ283217A (de) |
WO (1) | WO1995025170A1 (de) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT948358E (pt) * | 1996-12-24 | 2004-10-29 | Biogen Idec Inc | Formulacoes de interferao liquidas e estaveis |
TR200101087T2 (tr) | 1998-10-16 | 2001-09-21 | Biogen, Inc. | İnterferon beta-füzyon proteinleri ve kullanımları |
CN1329082C (zh) * | 1998-10-16 | 2007-08-01 | 拜奥根Idec马萨诸塞公司 | 干扰素-β-1a的聚合物缀合物及其使用 |
US6514729B1 (en) | 1999-05-12 | 2003-02-04 | Xencor, Inc. | Recombinant interferon-beta muteins |
US7431921B2 (en) * | 2000-04-14 | 2008-10-07 | Maxygen Aps | Interferon beta-like molecules |
US6531122B1 (en) * | 1999-08-27 | 2003-03-11 | Maxygen Aps | Interferon-β variants and conjugates |
US7144574B2 (en) * | 1999-08-27 | 2006-12-05 | Maxygen Aps | Interferon β variants and conjugates |
IL150109A0 (en) * | 1999-12-09 | 2002-12-01 | Chiron Corp | Method for administering a cytokine to the central nervous system and the lymphatic system |
US20020169290A1 (en) * | 2000-11-02 | 2002-11-14 | Claus Bornaes | New multimeric interferon beta polypeptides |
YU48703A (sh) | 2001-02-27 | 2006-05-25 | Maxygen Aps | Novi interferonu beta-slični molekuli |
AU2002254174A1 (en) * | 2001-03-13 | 2002-09-24 | Vical Incorporated | Interferon-beta polynucleotide therapy for autoimmune and inflammatory diseases |
US6887462B2 (en) | 2001-04-09 | 2005-05-03 | Chiron Corporation | HSA-free formulations of interferon-beta |
CA2463935A1 (en) * | 2001-09-18 | 2003-03-27 | Chiron Corporation | Methods for treating multiple sclerosis |
DK1578771T3 (da) | 2001-10-10 | 2013-06-10 | Novo Nordisk As | Remodellering og glycokonjugering af peptider |
EP2322229B1 (de) | 2001-10-10 | 2016-12-21 | Novo Nordisk A/S | Neumodulierung und Glykokonjugation von Faktor IX |
CA2498319A1 (en) * | 2002-09-09 | 2004-03-18 | Nautilus Biotech | Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules |
WO2004028472A2 (en) * | 2002-09-27 | 2004-04-08 | Biogen Idec Ma Inc. | THERAPIES FOR CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY USING INTERFERON-β |
WO2004031352A2 (en) * | 2002-10-01 | 2004-04-15 | Xencor, Inc. | Interferon variants with improved properties |
US20040175359A1 (en) * | 2002-11-12 | 2004-09-09 | Desjarlais John Rudolph | Novel proteins with antiviral, antineoplastic, and/or immunomodulatory activity |
SG155777A1 (en) | 2003-04-09 | 2009-10-29 | Neose Technologies Inc | Glycopegylation methods and proteins/peptides produced by the methods |
US8778880B2 (en) | 2004-02-02 | 2014-07-15 | Ambrx, Inc. | Human growth hormone modified at position 35 |
US7597884B2 (en) | 2004-08-09 | 2009-10-06 | Alios Biopharma, Inc. | Hyperglycosylated polypeptide variants and methods of use |
US20070179113A1 (en) * | 2005-05-19 | 2007-08-02 | Schering Aktiengesellachaft | GM-CSF gene therapy for Crohn's disease using an improved regulated expression system |
EP1885858A2 (de) * | 2005-05-19 | 2008-02-13 | Bayer Schering Pharma Aktiengesellschaft | Behandlung von krankheiten unter anwendung eines verbesserten regulierten expressionssystems |
TW200716749A (en) * | 2005-05-19 | 2007-05-01 | Schering Ag | Interferon-beta gene therapy using an improved, regulated expression system |
US20080076729A1 (en) * | 2005-05-19 | 2008-03-27 | Schering Aktiengesellachaft | Interferon-beta gene therapy using an improved, regulated expression system |
US20080219952A1 (en) * | 2005-08-26 | 2008-09-11 | Ares Trading S.A. | Process For the Preparation of Glycosylated Interferon Beta |
US20080038224A1 (en) * | 2006-03-28 | 2008-02-14 | Thierry Guyon | Modified interferon-beta (IFN-beta) polypeptides |
WO2008125222A2 (en) * | 2007-04-11 | 2008-10-23 | Bayer Schering Pharma Aktiengesellschaft | New modulation molecules for an improved regulated expression system |
WO2008134406A1 (en) * | 2007-04-25 | 2008-11-06 | The Board Of Trustees Of The Leland Stanford Junior University | Ischemia-induced neovascularization is enhanced by hcns-sc transplantation |
CA2685596A1 (en) * | 2007-05-02 | 2008-11-13 | Ambrx, Inc. | Modified interferon beta polypeptides and their uses |
US8273561B2 (en) * | 2007-10-05 | 2012-09-25 | Nuron Biotech, Inc. | High pressure treatment of aggregated interferons |
EP2379711B8 (de) * | 2008-12-23 | 2017-03-22 | BOCO Silicon Valley, Inc. | Zielpopulationen von oligodendrozyten-vorläuferzellen und verfahren zur herstellung und verwendung davon |
WO2019073315A1 (en) | 2017-10-09 | 2019-04-18 | Mansour Poorebrahim | ANALOGUE PEPTIDE OF INTERFERON-BETA |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0041313B1 (de) * | 1980-04-03 | 1990-09-12 | Biogen, Inc. | DNS-Sequenzen, rekombinante DNS-Moleküle und Verfahren zur Herstellung von dem menschlichen Fibroblast-Interferon |
US4992271A (en) * | 1982-09-23 | 1991-02-12 | Cetus Corporation | Formulation for lipophilic IL-2 proteins |
US4737462A (en) * | 1982-10-19 | 1988-04-12 | Cetus Corporation | Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β |
US4853332A (en) * | 1982-10-19 | 1989-08-01 | Cetus Corporation | Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of biologically active proteins |
US4588585A (en) * | 1982-10-19 | 1986-05-13 | Cetus Corporation | Human recombinant cysteine depleted interferon-β muteins |
FI82266C (fi) * | 1982-10-19 | 1991-02-11 | Cetus Corp | Foerfarande foer framstaellning av il-2 -mutein. |
US4518584A (en) * | 1983-04-15 | 1985-05-21 | Cetus Corporation | Human recombinant interleukin-2 muteins |
GB8317880D0 (en) * | 1983-07-01 | 1983-08-03 | Searle & Co | Structure and synthesis of interferons |
GB8334102D0 (en) * | 1983-12-21 | 1984-02-01 | Searle & Co | Interferons with cysteine pattern |
US4530787A (en) * | 1984-03-28 | 1985-07-23 | Cetus Corporation | Controlled oxidation of microbially produced cysteine-containing proteins |
GB8412564D0 (en) * | 1984-05-17 | 1984-06-20 | Searle & Co | Structure and properties |
US4959314A (en) * | 1984-11-09 | 1990-09-25 | Cetus Corporation | Cysteine-depleted muteins of biologically active proteins |
US4572798A (en) * | 1984-12-06 | 1986-02-25 | Cetus Corporation | Method for promoting disulfide bond formation in recombinant proteins |
US4816440A (en) * | 1985-09-26 | 1989-03-28 | Cetus Corporation | Stable formulation of biologically active proteins for parenteral injection |
EP0260350B1 (de) * | 1986-09-05 | 1992-02-12 | Cetus Oncology Corporation | Oxidationsresistente Muteine von beta-Interferon, deren Herstellung und diese Muteine enthaltende Präparate |
US5183746A (en) * | 1986-10-27 | 1993-02-02 | Schering Aktiengesellschaft | Formulation processes for pharmaceutical compositions of recombinant β- |
IL92124A (en) * | 1988-10-28 | 1996-10-31 | Sidney Pestka | Recombinant proteins modified to contain post-phosphorylation that do not occur in nature |
WO1993015609A1 (en) * | 1992-02-05 | 1993-08-19 | Thomas Jefferson University | Interferon gene therapy for the treatment of vascular disorders |
-
1994
- 1994-03-15 US US08/213,448 patent/US5545723A/en not_active Expired - Lifetime
-
1995
- 1995-03-13 EP EP95914045A patent/EP0750668B1/de not_active Expired - Lifetime
- 1995-03-13 AU AU21202/95A patent/AU695208B2/en not_active Expired
- 1995-03-13 NZ NZ283217A patent/NZ283217A/en not_active IP Right Cessation
- 1995-03-13 JP JP52414595A patent/JP3822903B2/ja not_active Expired - Lifetime
- 1995-03-13 CA CA002185352A patent/CA2185352C/en not_active Expired - Lifetime
- 1995-03-13 NZ NZ329970A patent/NZ329970A/xx not_active IP Right Cessation
- 1995-03-13 AT AT95914045T patent/ATE414152T1/de not_active IP Right Cessation
- 1995-03-13 DK DK95914045T patent/DK0750668T3/da active
- 1995-03-13 DE DE69535883T patent/DE69535883D1/de not_active Expired - Lifetime
- 1995-03-13 WO PCT/US1995/003206 patent/WO1995025170A1/en active Application Filing
-
1996
- 1996-09-13 NO NO19963837A patent/NO318989B1/no not_active IP Right Cessation
- 1996-09-13 FI FI963630A patent/FI120356B/fi not_active IP Right Cessation
-
1997
- 1997-08-18 US US08/912,768 patent/US6127332A/en not_active Expired - Lifetime
-
2006
- 2006-04-17 JP JP2006113870A patent/JP2006199711A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
AU695208B2 (en) | 1998-08-06 |
FI120356B (fi) | 2009-09-30 |
MX9604073A (es) | 1997-12-31 |
FI963630A0 (fi) | 1996-09-13 |
DK0750668T3 (da) | 2009-03-02 |
US6127332A (en) | 2000-10-03 |
JP3822903B2 (ja) | 2006-09-20 |
NO318989B1 (no) | 2005-05-30 |
NO963837L (no) | 1996-11-14 |
NZ329970A (en) | 2000-01-28 |
EP0750668A1 (de) | 1997-01-02 |
US5545723A (en) | 1996-08-13 |
CA2185352C (en) | 2005-02-22 |
NZ283217A (en) | 1998-05-27 |
NO963837D0 (no) | 1996-09-13 |
JPH10500563A (ja) | 1998-01-20 |
EP0750668B1 (de) | 2008-11-12 |
CA2185352A1 (en) | 1995-09-21 |
AU2120295A (en) | 1995-10-03 |
FI963630A (fi) | 1996-09-13 |
WO1995025170A1 (en) | 1995-09-21 |
ATE414152T1 (de) | 2008-11-15 |
JP2006199711A (ja) | 2006-08-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE414152T1 (de) | Muteine von ifn-beta | |
DK75694A (da) | Tumornecrosefaktor og derivater og mutantformer deraf, fremgangsmåde til fremstilling deraf, DNA som koder derfor, replicerbar udtrykkelsesvektor indeholdende DNA'en og celle transformeret dermed samt præparater omfattende tumornecrosefaktoren | |
NO914541L (no) | Fremgangsmaate ved fremstilling av tumor-nekrose-faktor-muteiner | |
RU95115239A (ru) | Аналог эритропоэтина | |
NO961639D0 (no) | Rekombinant adenovirusvektor og fremgangsmåte for anvendelse derav | |
NO931141L (no) | Tnf-muteiner | |
DK0880970T3 (da) | Anvendelse af farmaceutiske præparater der omfatter et anticytokin, til behandling af dissemineret sklerose | |
ATE91630T1 (de) | Pharmazeutische zusammensetzung zur verhuetung oder heilung von durch den papillomavirus induzierten tumoren. | |
WO2002074980A3 (en) | Muteins of hypoxia inducible factor alpha and methods of use thereof | |
TW275066B (de) | ||
EA200100395A1 (ru) | Фармацевтическая композиция, содержащая фрагменты днк, кодирующей антигенный белок, обладающая противоопухолевым действием | |
ES2080060T3 (es) | Proteinas que tienen actividad de union a interferon-gamma. | |
ATE100717T1 (de) | Intralaesionale behandlung von basalzellenkarzinoma mittels rekombinanten humanen alpha-interferons. | |
DE59208025D1 (de) | Neue thrombininhibitorische proteine aus landblutegeln | |
DE68908119T2 (de) | Arzneimittel zur Intralesionsbehandlung von schuppenartigem Zellkarzinomen mit rekombinantem human-alpha-Interferon. | |
IL132632A0 (en) | Dna encoding a gilr protein the protein its preparation and use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |